Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir/rilpivirine among early adopters in three U.S. clinics.
Christopoulos KA, Smith MB, Pareek P, Dawdani A, Erguera XA, Dance KV, Walker RS, Grochowski J, Mayorga-Munoz F, Hickey MD, Johnson MO, Sauceda J, Gutierrez JI Jr, Montgomery ET, Colasanti JA, Collins LF, McNulty MC, Koester KA.
Christopoulos KA, et al. Among authors: smith mb.
J Int AIDS Soc. 2024 Nov;27(11):e26394. doi: 10.1002/jia2.26394.
J Int AIDS Soc. 2024.
PMID: 39568168
Free PMC article.